Trade Regulus Therapeutics Inc. - RGLS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023318% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001096% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.52 |
| Open | 2.66 |
| 1-Year Change | 19.28% |
| Day's Range | 2.57 - 2.87 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 23, 2025 | 2.52 | 0.11 | 4.56% | 2.41 | 2.52 | 2.20 |
| Apr 22, 2025 | 2.30 | 0.34 | 17.35% | 1.96 | 2.30 | 1.96 |
| Apr 21, 2025 | 1.99 | -0.07 | -3.40% | 2.06 | 2.09 | 1.95 |
| Apr 17, 2025 | 2.03 | 0.12 | 6.28% | 1.91 | 2.07 | 1.90 |
| Apr 16, 2025 | 1.92 | 0.01 | 0.52% | 1.91 | 1.96 | 1.89 |
| Apr 15, 2025 | 1.93 | 0.02 | 1.05% | 1.91 | 2.04 | 1.91 |
| Apr 14, 2025 | 1.89 | 0.10 | 5.59% | 1.79 | 1.92 | 1.77 |
| Apr 11, 2025 | 1.75 | 0.04 | 2.34% | 1.71 | 1.81 | 1.61 |
| Apr 10, 2025 | 1.70 | 0.06 | 3.66% | 1.64 | 1.74 | 1.57 |
| Apr 9, 2025 | 1.68 | 0.18 | 12.00% | 1.50 | 1.69 | 1.50 |
| Apr 8, 2025 | 1.58 | -0.04 | -2.47% | 1.62 | 1.63 | 1.50 |
| Apr 7, 2025 | 1.57 | -0.01 | -0.63% | 1.58 | 1.76 | 1.54 |
| Apr 4, 2025 | 1.66 | -0.05 | -2.92% | 1.71 | 1.79 | 1.60 |
| Apr 3, 2025 | 1.78 | -0.01 | -0.56% | 1.79 | 1.92 | 1.71 |
| Apr 2, 2025 | 1.95 | 0.26 | 15.38% | 1.69 | 1.98 | 1.64 |
| Apr 1, 2025 | 1.76 | 0.07 | 4.14% | 1.69 | 2.02 | 1.64 |
| Mar 31, 2025 | 1.72 | 0.01 | 0.58% | 1.71 | 1.81 | 1.64 |
| Mar 28, 2025 | 1.72 | 0.25 | 17.01% | 1.47 | 1.72 | 1.47 |
| Mar 27, 2025 | 1.47 | 0.08 | 5.76% | 1.39 | 2.02 | 1.32 |
| Mar 26, 2025 | 1.26 | -0.04 | -3.08% | 1.30 | 1.32 | 1.25 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Regulus Therapeutics Inc. Company profile
About Regulus Therapeutics Inc
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multiple-ascending dose (MAD) clinical trial. RGLS4326, an anti-miR targeting miR-17, is for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It is in Phase I clinical trial. The Company’s pre-clinical pipeline candidates include RGLS5579 and anti-miR-132. RGLS5579 is developing for the treatment of Glioblastoma and anti-miR-132 is developing for the treatment of non-alcoholic steatohepatitis. Its developing two undisclosed products under Cell Therapies program and Hepatitis B virus program.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Regulus Therapeutics Inc revenues decreased from $10M to $0K. Net loss increased 77% to $27.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects research increase of 16% to $16.5M (expense), general increase of 15% to $7.9M (expense), Stock-based Compensation in SGA increase of 9% to $2.1M (expense).
Equity composition
Common stock $.001 Par, 10/12, 200M auth., 34,130,393 issd. Insider Owns 67.04%.
| Industry: | Bio Therapeutic Drugs |
Suite 210
3545 John Hopkins Court
92121
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com